Disease characteristics of the patients with PsA at HUNT3 (2008)
| Disease characteristics | All (n=151) | Male (n=64) | Female (n=87) |
| PsA disease duration, years (SD) | 4.8 (3.0) | 5.3 (3.2) | 4.5 (2.8) |
| Skin psoriasis disease duration, years, median (IQR) (n=78) | 9.0 (12.3) | 9.0 (12.3) | 8.5 (12.8) |
| Skin psoriasis symptom duration, years, median (IQR) (n=130) | 20 (24.4) | 18.9 (21.5) | 21.2 (28.4) |
| Peripheral joint involvement, n (%) | 146 (96.7) | 62 (96.9) | 84 (96.6) |
| Axial involvement, n (%) | 43 (28.5) | 20 (31.3) | 23 (26.4) |
| Enthesitis, n (%) | 101 (66.9) | 43 (67.2) | 58 (66.7) |
| CRP value, median (IQR) | 4.0 (4) (n=143) | 4.0 (4) (n=59) | 4.0 (6) (n=84) |
| ESR value, median (IQR) | 9.0 (14) (n=139) | 6.0 (9) (n=57) | 10.0 (15) (n=82) |
| Ever use of peroral steroids, n (%) | |||
| Previous | 66 (43.7) | 22 (34.4) | 44 (50.6) |
| Current | 6 (4.0) | 3 (4.7) | 3 (3.4) |
| Ever users of anti-TNF therapy, n (%) | |||
| Previous | 10 (6.6) | 1 (1.6) | 9 (10.3) |
| Current | 15 (9.9) | 6 (9.4) | 9 (10.3) |
| Ever use of methotrexate, n (%) | |||
| Previous | 29 (19.2) | 10 (15.6) | 19 (21.8) |
| Current | 45 (29.8) | 21 (32.8) | 24 (27.6) |
| Ever use of synthetic DMARDs other than methotrexate, n (%) | |||
| Leflunomide | 37 (24.5) | 12 (18.8) | 25 (28.7) |
| Sulfasalazin | 8 (5.3) | 2 (3.1) | 6 (6.9) |
Unless stated, continuous values are mean (SD), categorical values are number (%).
CRP, C reactive protein; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HUNT3: Health Study in Nord-Trøndelag 3; PsA, psoriatic arthritis; TNF, tumour necrosis factor.